Goldman Sachs Knock-Out LLY/ DE000GP7WPU9 /
11/13/2024 7:49:23 PM | Chg.+0.50 | Bid10:00:26 PM | Ask10:00:26 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
70.10EUR | +0.72% | - Bid Size: - |
- Ask Size: - |
Eli Lilly and Co | 78.9499 USD | 12/31/2078 | Call |
Newsfile Corp
9/16
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Newsfile Corp
8/28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
8/27
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire
8/21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
8/21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
8/14
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
8/14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
8/8
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/8
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
8/7
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
8/6
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
8/6
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire
8/2
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
8/1
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
8/1
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives